Economy

Philippines’ FDA approves Pfizer vaccine for emergency use

The Philippines has approved Pfizer Inc.-BioNTech SE’s COVID-19 vaccine, the first to be allowed for emergency use in the country.

The Food and Drug Administration found Pfizer’s vaccine may be effective to prevent, diagnose or treat COVID-19, and can be used for individuals age 16 years old and up, its head Eric Domingo said in a virtual briefing.

Sinovac Biotech Ltd. has applied for a similar authority on Wednesday, and the regulator will ask for more clinical trial reports, Domingo said.

Pfizer vaccines may be among the first to arrive in the Philippines next month through the World Health Organization-backed COVAX facility, vaccine czar Carlito Galvez said at a briefing with President Rodrigo R. Duterte on Wednesday. The government is also in talks with Pfizer for up to 40 million doses, Mr. Galvez said.  —  Cecilia Yap and Andreo Calonzo/Bloomberg

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Your daily news source covering investing ideas, market stocks, business, retirement tips from Wall St. to Silicon Valley.

Disclaimer:

TheProficientInvestor.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 TheProficientInvestor. All Rights Reserved.

To Top
ENJOY YOUR FREE SUBSCRIPTION!
Get In-depth Understanding Of The Stock Markets With The Top Headlines Emailed Directly To You Every Day.
We follow a strict anti-spam policy. You may cancel your subscription at any time.